NCT03542149

Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Phase 1b to Assess Safety, Tolerability, Pharmacokinetic Profile, and Antimalarial Activity of Single Doses of Co-administered OZ439and PQP Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Medicines for Malaria Venture · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A single-centre Phase 1b study to assess the safety, tolerability, pharmacokinetic profile, and antimalarial activity of single doses of coadministered artefenomel (OZ439) and piperaquine phosphate (PQP) against early Plasmodium falciparum blood stage infection in healthy adult volunteers.

Detailed description

This is a single-centre, open-label, adaptive, study using the P. falciparum induced blood stage malaria (IBSM) inoculum as a model to characterise the pharmacodynamic (PD) activity of combined single dose administration of OZ439 and PQP. The study will be conducted in a maximum of three cohorts (up to 8 subjects per cohort) using up to 4 different doses of OZ439 and PQP in each cohort. Subjects will be malaria naïve healthy males or females, aged between 18-55 years old, who meet all of the inclusion criteria and none of the exclusion criteria. The first cohort will be composed of 4 groups of 2 subjects each. Subjects will be randomised into one of 4 dose groups and administered single oral doses of OZ439 and PQP in combination The combined dose of OZ439 and PQP will be different for each of the 4 groups in this cohort as shown in Table 1. Table 1 OZ439 and PQP Cohort 1 Dose Drug Dose group 1A 1B 1C 1D OZ439 (mg) 200 200 400 400 PQP (mg) 480 640 480 640 The data captured from this first cohort will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels. Based on safety and tolerability data up to Day 35 post-dose, and pharmacokinetic/pharmacodynamic (PK/PD) analysis outcomes (based on PD data up to Day 35 and PK data up to Day 28 post-dose) of the drugs given in combination, the dose(s) for the subsequent cohort will be determined. A similar analysis will be done at the end of cohort 2 combining cohorts 1 and 2 data to decide the dose(s) to be tested in cohort 3. This will be decided by the funding sponsor and the Principal Investigator following review of the data by the Safety and Data Review Team (SDRT) and scientific evaluation. The doses used in all cohorts will not exceed the maximum acceptable doses predefined for this study (800 mg for OZ439 and 1440 mg for PQP) as determined in previous safety, pilot efficacy and phase 2 studies. Each subject will be inoculated on Day 0 with approximately 2,800 viable parasites of P. falciparum-infected human erythrocytes administered intravenously. Subjects will be followed up daily via phone call or text message on Days 1 to 3 post-inoculation to solicit any AEs. Subjects will then come to the clinical unit once daily from Day 4 until presence of asexual parasites is established by quantitative polymerase chain reaction (qPCR) targeting the 18S rRNA gene (referred to hereafter as malaria 18S qPCR). Once qPCR becomes positive and until OZ439 and PQP administration, subjects will come to the clinical unit twice-daily, separated by approximately 12 hours, for clinical evaluation and blood sampling. Subjects will be admitted to the clinical unit for single dose administration of OZ439 and PQP 8 days after malaria inoculation or at Investigators discretion (i.e. as per parasitaemia levels). Subjects will be followed up as inpatients for at least 72 hours to ensure tolerance of the investigational treatments and clinical response, then if clinically well on an outpatient basis for safety and clearance of malaria parasites via qPCR. After discharge from the clinical unit, subjects will be followed up regularly for safety assessments, PK sampling, clinical evaluation, and malaria qPCR blood sampling until 35 days after OZ439 and PQP administration. All subjects will receive a standard course of therapy with Riamet® (artemether-lumefantrine) 34 days after OZ439 and PQP administration, or earlier in the event of failure of clearance of parasitaemia or recrudescence of parasitaemia. The presence of gametocytes in subjects' blood will be determined by parasite lifecycle stage qRT-PCR or by the presence of stable low level parasitaemia. If gametocytes are present at the time of treatment with Riamet®, Primacin™ (primaquine) will also be administered as a single oral dose. AEs (AEs) will be monitored via telephone, within the clinical unit, and on outpatient review after malaria challenge inoculation and antimalarial study drugs administration. Blood samples for safety evaluation, malaria monitoring, and red blood cell antibodies will be drawn at screening and/or baseline and at nominated times after malaria challenge.

Conditions

• Malaria

Interventions

Type	Name	Description
DRUG	480 mg Piperaquine phosphate	480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
DRUG	640 mg Piperaquine phosphate	640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
DRUG	200 mg OZ 439	200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
DRUG	400 mg OZ 439	400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
DRUG	800 mg OZ 439	800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
DRUG	960 mg PQP	960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
DRUG	320 mg PQP	320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.

Timeline

• Start date: 2018-04-23
• Primary completion: 2019-04-19
• Completion: 2019-04-19
• First posted: 2018-05-31
• Last updated: 2024-05-10
• Results posted: 2024-05-10

Locations

1 site across 1 country: Australia